The first clinical imaging study on patients with breast cancer was conducted using HER2-specific affibody, which was labelled with 111In or 68Ga using both SPECT (single-photon emission computerized tomography) and PET (positron emission tomography) imaging [26,48]. Here, ERBB2 is linked to breast carcinoma.